Hot Features
プレミアム
Neurogene Inc (NGNE)
NASDAQ
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional ge... Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. 詳細を表示
Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome Neurogene to advance NGN-401 at 1E15 vg dose Expects to provide an update on...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update...
All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed...
Financing included participation from top-tier healthcare funds Proceeds expected to fund Company into the second half of 2027 Company to host webcast to review interim clinical data from Phase...
Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (Nasdaq: NGNE), a...
NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needs NGN-401 selected for FDA...
Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome RMAT designation provides an...
Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that...
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile Interim safety data presented at the International Rett Syndrome Foundation (IRSF...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.99 | -11.1943092475 | 26.71 | 26.75 | 20.82 | 421139 | 23.2782436 | CS |
| 4 | -46.06 | -66.007451992 | 69.78 | 74.49 | 14.44 | 780902 | 27.55633773 | CS |
| 12 | -17.26 | -42.1181063934 | 40.98 | 74.49 | 14.44 | 355564 | 34.60099084 | CS |
| 26 | -13.4 | -36.099137931 | 37.12 | 74.49 | 14.44 | 232908 | 35.52930534 | CS |
| 52 | 9.15 | 62.8002745367 | 14.57 | 74.49 | 12.49 | 174484 | 35.61203405 | CS |
| 156 | 9.15 | 62.8002745367 | 14.57 | 74.49 | 12.49 | 174484 | 35.61203405 | CS |
| 260 | 9.15 | 62.8002745367 | 14.57 | 74.49 | 12.49 | 174484 | 35.61203405 | CS |
Monksdream
3月前
LegendaryNomad22
6月前
Monksdream
9月前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
